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• assess. v^aluation of the Economic Impact of Pharmacist Involvement 
- "tents in Hyperalimentation Therapy 
Larry Crots, RPh,* and Larry Shoup, MS^  
A prospective parallel study of patients receiving total parenteral nutrition (TPN) was undertaken to 
identify characteristics of TPN solution use and wasle. Thirty consecutive patients receiving TPN by 
order ofthe primary chnical service (control group) were compared with 25 consecutive patients 
receiving TPN under the supervision and monitoring of the Nutritional Support Service (study group). 
The patients were evenly divided between medical and .surgical problems, with 53% of the control 
group being surgical patients compared to 56% ofthe study group. There were 136 L of TPN or 4.5 
Upatient discarded in the control group compared to 65 Lor 2.6 L/patient discarded in the study 
group. This wastage expressed as a percentage is 13.2% for the control group and 7.1% for the study 
group. Pharmacist involvement in TPN monitoring and supervision was associaied with a 46% 
decrease in solution waste. The data from this study suggest that pharmacist involvement in TPN 
monitoring and supervision may be cost-effective. (Henry Ford Hosp Med J 1986;34:99-100) 
I 
Parenteral nutrition solutions constitute a major component ofthe cost of total parenteral nutrition (TPN) therapy (1). As 
an integral member of the nutritional support team, the phar-
macist is uniquely qualified to assist in maximizing the effective 
use and minimizing the waste of TPN solutions. The impact of 
pharmacist monitoring of TFN usage to help decrease waste is 
not well known (2,3). This prospective study was undertaken to 
determine the effect of pharmacists' monitoring of TPN solution 
use. 
Materials and Methods 
Beginning in July 1982, during a three-month period, 30 con-
secutive patients receiving TPN by order of the primary clinical 
service (control group) were identified and compared to 25 con-
secutive patients receiving TPN under supervision and monitor-
ing of the nutritional support team (study group). These two 
groups were compared in terms of TPN solution use and waste. 
The TPN team pharmacist actively participated in planning 
and monitoring therapy for the 25 study group patients. The 
pharmacist was attentive to activities which would promote ef-
fective ordering and use of TPN solutions while decreasing the 
number of solutions that were prepared but not administered. 
Examples of these activities include the following: 
1. Physicians were encouraged to correct electrolyte im-
balances by adjusting peripheral intravenous (IV) therapy or 
enteral therapy rather than changing already prepared TPN 
solutions. 
2. Physicians were encouraged to alter future TPN solution 
formulations with the next solution to be infused. 
3. The inpatient pharmacy was promptly notified of solution 
changes to decrease unnecessary solution preparation. 
4. Clinical and laboratory data were monitored to anticipate 
"•equired changes in formulation. 
5. Altematives to parenteral nutrition were suggested when 
appropriate. 
Results 
The results of this prospective study are summarized in the 
Table. Demographically, the control and study group patients 
were similar. Both groups also had similar courses of TPN 
therapy. 
The Table illustrates substantial differences between the two 
groups in liters of TPN solution discarded during therapy. In the 
control group, 136 L of TPN or 4.5 L/patient were discarded 
compared to 65 L of TPN or 2.6 L/patient in the study group. 
The percentage waste (total liters wasted divided by total liters 
infused) was 13.2% for the control group and 7.1% for the study 
group. Of the parenteral nutrition regimens prescribed, ten of 
the 30 patients (33%) in the control group utilized peripheral hy-
peralimentation. In the study group, three of the 25 patients 
(12%) utilized peripheral hyperalimentation, which was a 21% 
reduction in peripheral hyperalimentation use. 
Wastage of TPN solutions in primary service administration 
(control group) was high, 4.5 L of TPN solution per patient. 
Expressed as dollars, based on a manufacturer's list price of 
$46.71/L, this loss averaged $210.20/patient in solution costs 
alone. In the study group only 2.6 L/patient of TPN solution 
were wasted. The difference between the control and study 
groups amounted to $93.43/patient. 
Discussion 
Nutritional support is expensive, particularly in the form of 
parenteral nutrition. In 1982, approximately 450 Henry Ford 
Hospital patients received this form of therapy at an average 
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Table 
Suinmary Comparison of Control and Study Groups 
(Demographics and TPN Use and Waste) 
Control Group Study Group 
Number of patients 30 25 
Patient age 
Average years (range) 60.8 (22 to 92) 50.6 (15 to 75) 
Sex: male/female 21/9 17/8 
Primary service (No. of patients) 
Medicine 14 11 
Surgery 1(1 14 
Duration of TPN therapy 
Average (days) 13.1 13.4 
Range 5 to 34 6 to 24 
Liters of TPN infused 
Total 1,029 920 
Average/patient 34.3 36.8 
Range 12 to 90 16 to 60 
Liters wasted 
Total 1 36 (i.-s 
Average/patient 4.5 2.6 
% Wastage 
(Total unused/total infused) 13.2% 7.1% 
% Peripheral hyperalimentation 33.3% 12% 
annual retail cost of $815,000 per year. The estimate that ap-
proximately $1 billion were spent in the United States in 1985 
for solutions and equipment illustrates this costly therapeutic 
modality (4). 
Since most cases referred to the nutritional support team are 
complicated and beyond their DRG cash allotment, nutritional 
support teams are facing an economic pressure to disband. The 
argument for keeping the team relies on the proven safety and 
efficacy of nutritional support when managed according to 
protocol. Complications and waste associated with overfeed-
ing, underfeeding, or inappropriate feeding may result in cost 
increases that far outweigh the cost of the team (5). 
In this study pharmacist involvement in TPN monitoring and 
supervision was associated with a 46% decrease in central ve-
nous solution waste compared to the control group. This reduc-
tion in solution waste when calculated on 450 patients amounts 
to $79,874 per yean This improved efficiency of solution use 
was accomplished with careful attention to needed changes in 
therapy and a thorough understanding of formulation schedules 
in the pharmacy. 
The 21% reduction of peripheral hyperalimentation use was 
accomplished in two ways: 1) by using the gastrointestinal tract 
when possible with tube feedings and/or oral supplements rather 
than peripheral therapy, or 2) by instituting central venous hy-
peralimentation if the duration of therapy warranted a prolonged 
course of IV nutritional support longer than ten days. The cost 
difference in central venous hyperalimentation and peripheral 
hyperalimentation is approximately $34.68 per day. This addi-
i 
tional cost, applied to 33% of 450 patients, amounts to $67,175 
per year The peripheral venous route is a more expensive mode 
of therapy because of the extensive use of IV fat emulsions as a 
primary caloric source. Based on retail costs of hyperalimenta-
tion solutions, pharmacist intervention in these few areas could 
reduce costs by approximately $122,700 per year. Thus, the 
pharmacist's role in this area of therapeutic management is ben-
eficial on both clinical and economic grounds (6-8). 
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